Taysha Gene Therapies
TSHA
4.43
+0.04
+0.91%
Taysha Gene Therapies
US · TSHA
#3015 by market cap
Listed 2020
4.43
+0.04
+0.91%
Live - 5344 symbols - heartbeat 500s ago
· 2026-10-08 04:03
Pre-market
4.41
-0.45%
After-hours
4.43
0.00%
- Market cap
- 1.44B
- P/E (TTM)i
- -10.80
- P/Bi
- 3.73
- EPSi
- -0.34
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on TSHA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
14.60 +229.6%
Price target rangecurrent 4.43
Low12.00
Avg14.60
High19.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-17 | Wolfe Research | -- | BUY | -- |
| 2026-08-14 | BofA Securities | -- | BUY | -- |
| 2026-08-12 | Piper Sandler | -- | BUY | 12.00 |
| 2026-08-12 | Needham | -- | BUY | 12.00 |
| 2026-08-11 | Cantor Fitzgerald | -- | BUY | 19.00 |
| 2026-08-11 | CCORF | -- | BUY | 17.00 |
| 2026-08-11 | Goldman Sachs | -- | BUY | 13.00 |
| 2026-07-20 | Goldman Sachs | -- | BUY | 13.00 |
| 2026-07-01 | Needham | -- | BUY | 12.00 |
| 2026-06-30 | Piper Sandler | -- | BUY | 12.00 |
| 2026-06-30 | Baird | -- | BUY | 15.00 |
| 2026-06-30 | Needham | -- | BUY | 12.00 |
| 2026-06-30 | BMO Capital | -- | BUY | 14.00 |
| 2026-06-23 | Citizens JMP | -- | BUY | 11.00 |
| 2026-06-23 | BMO Capital | -- | BUY | 14.00 |
| 2026-06-22 | BofA Securities | -- | BUY | 10.00 |
| 2026-06-22 | Needham | -- | BUY | 12.00 |
| 2026-05-07 | Wells Fargo | -- | BUY | 11.00 |
| 2026-05-06 | CCORF | -- | BUY | 17.00 |
| 2026-05-06 | Needham | -- | BUY | 12.00 |
| 2026-04-15 | Needham | -- | BUY | 12.00 |
| 2026-04-06 | CCORF | -- | BUY | 17.00 |
| 2026-03-24 | Cantor Fitzgerald | -- | BUY | 19.00 |
| 2026-03-19 | Needham | -- | BUY | 12.00 |
| 2026-03-19 | Goldman Sachs | -- | BUY | 11.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-11 | -- | ±16.55% | +4.87% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±16.94% | +0.58% (in line) |
| 2025/Q4 | 2026-03-19 | -- | ±18.21% | +2.47% (in line) |
| 2025/Q3 | 2025-11-04 | -- | ±25.78% | -4.26% (in line) |
| 2025/Q2 | 2025-08-12 | -- | ±27.36% | +5.43% (in line) |
| 2025/Q1 | 2025-05-15 | -- | ±39.49% | +8.02% (in line) |
| 2024/Q4 | 2025-02-26 | -- | ±50.80% | -4.71% (in line) |
| 2024/Q3 | 2024-11-13 | After close | ±30.32% | +2.71% (in line) |
| 2024/Q2 | 2024-08-12 | -- | ±33.49% | -2.39% (in line) |
| 2024/Q1 | 2024-05-14 | After close | ±28.44% | +21.01% (in line) |
| 2023/Q4 | 2024-03-19 | After close | ±45.16% | +31.56% (in line) |
| 2023/Q3 | 2023-11-14 | After close | ±41.85% | +26.32% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:03:15 · For reference only, not investment advice and not tailored to your situation.